566 related articles for article (PubMed ID: 30222111)
1. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamine.
Curto-Barredo L; Giménez-Arnau AM
G Ital Dermatol Venereol; 2019 Aug; 154(4):444-456. PubMed ID: 30717573
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
5. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
Front Immunol; 2021; 12():635069. PubMed ID: 33737936
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
Giménez-Arnau AM
Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
[TBL] [Abstract][Full Text] [Related]
9. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
[TBL] [Abstract][Full Text] [Related]
11. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
[TBL] [Abstract][Full Text] [Related]
13. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
Salman A; Ergun T; Gimenez-Arnau AM
J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
[No Abstract] [Full Text] [Related]
14. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
[TBL] [Abstract][Full Text] [Related]
15. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
MacGlashan D; Saini S; Schroeder JT
J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
17. Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria.
Apalla Z; Sidiropoulos T; Kampouropoulou E; Papageorgiou M; Lallas A; Lazaridou E; Smaragdi M; Delli F
Eur J Dermatol; 2020 Dec; 30(6):716-722. PubMed ID: 33258453
[TBL] [Abstract][Full Text] [Related]
18. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
Magen E; Waitman DA; Kahan NR
Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
[No Abstract] [Full Text] [Related]
19. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
Farrah G; Stevenson B; Lie K; Brusch A
Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
[TBL] [Abstract][Full Text] [Related]
20. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]